Proprio, a medical technology company enabling enhanced surgical performance through the proprietary combination of computer vision, machine learning, and immersive technology, is pleased to announce Dr. Linda Maxwell of DCVC (Data Collective) has joined as a Board Observer.
Dr. Maxwell is a double board-certified ENT surgeon and Operating Partner at DCVC, a top tier Silicon Valley Deep Tech venture fund where she focuses on healthcare and life sciences technology. As the Founder and Executive Director of the Biomedical Zone, Canada’s first and only hospital-embedded, physician-led medtech incubator, she has developed more than 70 startups and facilitated more than $60M in private investments.
“We’re immensely proud to welcome Dr. Maxwell to Proprio’s Board of Directors,” Gabriel Jones, CEO and Co-founder of Proprio noted. “Dr. Maxwell’s accomplishments in medtech and digital health are remarkable, and we look forward to her insights as a clinician and business leader on our renowned team of advisors.”
“As an Operating Partner at DCVC, I am thrilled to join Proprio’s Board and continue to foster our support for the revolutionary technologies they are developing,” Dr. Maxwell emphasized. “Our team continues to be impressed by the strides Proprio has made in computer vision and data intelligence for enhancing surgical outcomes. I look forward to being involved in this exciting phase of the company’s growth.”
Proprio is a medical technology company based in Seattle, Washington. We enable the new way of seeing™ in surgery through a proprietary platform that synthesizes artificial intelligence, computer vision, augmented reality, and robotics. Proprio’s goal is to dramatically improve clinical and economic outcomes through the combination of physician expertise and immersive, intelligent technology. Proprio is backed by leading healthcare and technology investors, including DCVC (Data Collective), BOLD Capital Partners, Cota Capital, Intel, HTC, and Alan Frazier, founder of Frazier Healthcare Partners. For more information, visitwww.propriovision.com.
ABOUT DR. LINDA MAXWELL
Dr. Linda Maxwell is driven by a lifelong commitment to better health for ALL people through science, innovation, and ingenuity. A double board-certified ENT surgeon, she is currently an Operating Partner at DCVC, a top tier Silicon Valley Deep Tech venture fund where she focuses on healthcare and life sciences technology. She is also the Founding and Executive Director of the Biomedical Zone, Canada’s first and only, hospital-embedded, physician-led med tech incubator. Since founding the Biomedical Zone in 2015, she has developed over 70 med tech and digital health startup companies with several exits, facilitating over $60 million in private investment. Her startups have engaged hundreds of clinicians and have impacted over 67,000 patients. An Adjunct Professor of Surgery at the University of Toronto and Associate Scientist at the Li Ka Shing Knowledge Institute in Toronto, she is a published scientific author, medical educator, and frequent public speaker.
Dr. Maxwell has been recognized as Canada’s Top 100 Most Powerful Women by the Women’s Executive Network, Top 30 Women Making a Difference in Tech, Top 100 Accomplished Black Women in Canada. She is the recipient of the Hayes Prize in Operations Management from Oxford and the Grayson Administrative Leadership Award from Toronto Metropolitan University.
Dr. Maxwell earned a bachelor’s degree in Biology with honors from Harvard University, an M.D. from Yale University, and an M.B.A. from the University of Oxford. She completed six years of residency and fellowship training in Otolaryngology-Head Neck Surgery at the University of Toronto and is double-board certified in Otolaryngology and Facial Plastic Reconstructive Surgery. She is passionate about good corporate governance. She is a certified Independent Corporate Director (ICD.D) and is pursuing the Diligent Climate Leadership Certificate. Her boards/committees include: United Therapeutics, Audit; ImmunityBio, Compensation Chair, Audit, Related Party Transactions; Public Health Agency of Canada, Departmental Audit Committee (Federal appointment).